Apellis Historical Income Statement
| APLS Stock | USD 24.27 0.01 0.04% |
Historical analysis of Apellis Pharmaceuticals income statement accounts such as Interest Expense of 42.4 M, Selling General Administrative of 526.1 M or Other Operating Expenses of 993.7 M can show how well Apellis Pharmaceuticals performed in making a profits. Evaluating Apellis Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Apellis Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Apellis Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Apellis Pharmaceuticals is a good buy for the upcoming year.
Apellis |
About Apellis Income Statement Analysis
Apellis Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Apellis Pharmaceuticals shareholders. The income statement also shows Apellis investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Apellis Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Apellis Pharmaceuticals. It is also known as Apellis Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Apellis Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Apellis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apellis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.At this time, Apellis Pharmaceuticals' Tax Provision is comparatively stable compared to the past year.
| 2022 | 2023 | 2024 | 2025 (projected) | Reconciled Depreciation | 1.5M | 1.7M | 1.8M | 1.2M | Interest Income | 8.9M | 20.9M | 12.8M | 7.6M |
Apellis Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Apellis Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Apellis Pharmaceuticals income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 859K | 1.5M | 1.5M | 1.7M | 1.8M | 1.7M | |
| Interest Expense | 29.9M | 13.2M | 32.6M | 29.6M | 40.4M | 42.4M | |
| Selling General Administrative | 139.4M | 176.8M | 277.2M | 500.8M | 501.1M | 526.1M | |
| Other Operating Expenses | 464.4M | 602.8M | 670.0M | 913.7M | 946.3M | 993.7M | |
| Operating Income | (213.7M) | (536.3M) | (594.6M) | (517.1M) | (236.4M) | (248.2M) | |
| Ebit | (313.1M) | (732.8M) | (618.9M) | (496.9M) | (238.2M) | (250.1M) | |
| Research Development | 299.9M | 420.9M | 387.2M | 354.4M | 327.6M | 202.0M | |
| Ebitda | (312.2M) | (731.3M) | (617.4M) | (495.2M) | (236.4M) | (248.2M) | |
| Total Operating Expenses | 439.3M | 597.6M | 664.4M | 855.2M | 828.6M | 870.1M | |
| Income Before Tax | (343.0M) | (746.0M) | (651.5M) | (526.5M) | (196.7M) | (206.6M) | |
| Total Other Income Expense Net | (129.3M) | (209.7M) | (56.9M) | (9.4M) | 39.7M | 41.7M | |
| Net Income | (344.9M) | (746.4M) | (652.2M) | (528.6M) | (197.9M) | (207.8M) | |
| Total Revenue | 250.6M | 66.6M | 75.4M | 396.6M | 710.0M | 745.5M | |
| Gross Profit | 225.6M | 61.4M | 69.8M | 338.1M | 592.2M | 621.8M | |
| Net Income From Continuing Ops | (344.9M) | (746.4M) | (652.2M) | (528.6M) | (197.9M) | (207.8M) | |
| Cost Of Revenue | 25.1M | 5.2M | 5.6M | 58.5M | 117.7M | 67.9M | |
| Net Income Applicable To Common Shares | (304.7M) | (344.9M) | (746.4M) | (652.2M) | (587.0M) | (557.6M) | |
| Income Tax Expense | 1.8M | 352K | 669K | 2.1M | 1.2M | 1.2M | |
| Net Interest Income | (25.8M) | (12.8M) | (23.7M) | (8.6M) | (27.6M) | (26.2M) | |
| Interest Income | 4.2M | 418K | 8.9M | 20.9M | 12.8M | 7.6M | |
| Reconciled Depreciation | 637K | 1.5M | 1.5M | 1.7M | 1.8M | 1.2M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.